vs
Pacira BioSciences, Inc.（PCRX）与医疗房产信托（SVC）财务数据对比。点击上方公司名可切换其他公司
医疗房产信托的季度营收约是Pacira BioSciences, Inc.的1.7倍（$296.5M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -0.3%，领先1.9%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -17.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -6.1%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
医疗房产信托（MPT）是总部位于阿拉巴马州伯明翰的国际房地产投资信托（REIT），主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司的房产收购多采用售后回租模式，原产权方出售房产给MPT后成为承租租户，其租户普遍签订长期三净租约。
PCRX vs SVC — 直观对比
营收规模更大
SVC
是对方的1.7倍
$177.4M
营收增速更快
PCRX
高出22.0%
-17.0%
净利率更高
PCRX
高出1.9%
-0.3%
两年增速更快
PCRX
近两年复合增速
-6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $296.5M |
| 净利润 | $2.9M | $-782.0K |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | -3.9% |
| 净利率 | 1.6% | -0.3% |
| 营收同比 | 5.0% | -17.0% |
| 净利润同比 | — | 99.0% |
| 每股收益（稀释后） | $0.07 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXSVC
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $296.5M | ||
| Q3 25 | $179.5M | $377.6M | ||
| Q2 25 | $181.1M | $404.4M | ||
| Q1 25 | $168.9M | $335.0M | ||
| Q4 24 | $187.3M | $357.0M | ||
| Q3 24 | $168.6M | $390.9M | ||
| Q2 24 | $178.0M | $412.5M |
净利润PCRXSVC
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-782.0K | ||
| Q3 25 | $5.4M | $-46.9M | ||
| Q2 25 | $-4.8M | $-38.2M | ||
| Q1 25 | $4.8M | $-116.4M | ||
| Q4 24 | — | $-76.4M | ||
| Q3 24 | $-143.5M | $-46.9M | ||
| Q2 24 | $18.9M | $-73.8M |
毛利率PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXSVC
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -3.9% | ||
| Q3 25 | 3.5% | -12.8% | ||
| Q2 25 | 4.7% | -9.2% | ||
| Q1 25 | 1.2% | -33.3% | ||
| Q4 24 | 13.2% | -19.4% | ||
| Q3 24 | -82.8% | -12.8% | ||
| Q2 24 | 15.9% | -17.1% |
净利率PCRXSVC
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -0.3% | ||
| Q3 25 | 3.0% | -12.4% | ||
| Q2 25 | -2.7% | -9.4% | ||
| Q1 25 | 2.8% | -34.8% | ||
| Q4 24 | — | -21.4% | ||
| Q3 24 | -85.1% | -12.0% | ||
| Q2 24 | 10.6% | -17.9% |
每股收益（稀释后）PCRXSVC
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.01 | ||
| Q3 25 | $0.12 | $-0.28 | ||
| Q2 25 | $-0.11 | $-0.23 | ||
| Q1 25 | $0.10 | $-0.70 | ||
| Q4 24 | $0.38 | $-0.46 | ||
| Q3 24 | $-3.11 | $-0.28 | ||
| Q2 24 | $0.39 | $-0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $346.8M |
| 总债务越低越好 | — | $5.5B |
| 股东权益账面价值 | $653.9M | $646.1M |
| 总资产 | $1.2B | $6.5B |
| 负债/权益比越低杠杆越低 | — | 8.52× |
8季度趋势，按日历期对齐
现金及短期投资PCRXSVC
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $346.8M | ||
| Q3 25 | $246.3M | $417.4M | ||
| Q2 25 | $445.9M | $63.2M | ||
| Q1 25 | $493.6M | $80.1M | ||
| Q4 24 | $484.6M | $143.5M | ||
| Q3 24 | $453.8M | $48.6M | ||
| Q2 24 | $404.2M | $14.6M |
总债务PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $5.5B | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $5.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXSVC
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $646.1M | ||
| Q3 25 | $727.2M | $647.9M | ||
| Q2 25 | $757.8M | $695.9M | ||
| Q1 25 | $798.5M | $734.6M | ||
| Q4 24 | $778.3M | $851.9M | ||
| Q3 24 | $749.6M | $929.0M | ||
| Q2 24 | $879.3M | $1.0B |
总资产PCRXSVC
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $6.5B | ||
| Q3 25 | $1.3B | $7.0B | ||
| Q2 25 | $1.5B | $6.9B | ||
| Q1 25 | $1.6B | $7.0B | ||
| Q4 24 | $1.6B | $7.1B | ||
| Q3 24 | $1.5B | $7.1B | ||
| Q2 24 | $1.6B | $7.1B |
负债/权益比PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 8.52× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 6.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-95.2M |
| 自由现金流率自由现金流/营收 | — | -32.1% |
| 资本支出强度资本支出/营收 | — | 25.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-107.0M |
8季度趋势，按日历期对齐
经营现金流PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-18.5M | ||
| Q3 25 | $60.8M | $98.1M | ||
| Q2 25 | $12.0M | $-7.0K | ||
| Q1 25 | $35.5M | $38.2M | ||
| Q4 24 | $33.1M | $-9.7M | ||
| Q3 24 | $53.9M | $106.2M | ||
| Q2 24 | $53.2M | $43.8M |
自由现金流PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-95.2M | ||
| Q3 25 | $57.0M | $57.9M | ||
| Q2 25 | $9.3M | $-46.6M | ||
| Q1 25 | $26.9M | $-23.2M | ||
| Q4 24 | $31.0M | $-88.9M | ||
| Q3 24 | $49.8M | $24.1M | ||
| Q2 24 | $51.6M | $-22.3M |
自由现金流率PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -32.1% | ||
| Q3 25 | 31.7% | 15.3% | ||
| Q2 25 | 5.1% | -11.5% | ||
| Q1 25 | 15.9% | -6.9% | ||
| Q4 24 | 16.6% | -24.9% | ||
| Q3 24 | 29.6% | 6.2% | ||
| Q2 24 | 29.0% | -5.4% |
资本支出强度PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 25.9% | ||
| Q3 25 | 2.2% | 10.6% | ||
| Q2 25 | 1.5% | 11.5% | ||
| Q1 25 | 5.1% | 18.3% | ||
| Q4 24 | 1.1% | 22.2% | ||
| Q3 24 | 2.4% | 21.0% | ||
| Q2 24 | 0.9% | 16.0% |
现金转化率PCRXSVC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SVC
暂无分部数据
